Published in Addiction on November 01, 2008
Subjective responses to alcohol consumption as endophenotypes: advancing behavioral genetics in etiological and treatment models of alcoholism. Subst Use Misuse (2010) 1.39
Early adoption of injectable naltrexone for alcohol-use disorders: findings in the private-treatment sector. J Stud Alcohol Drugs (2010) 1.22
The Effects of Naltrexone Among Alcohol Non-Abstainers: Results from the COMBINE Study. Front Psychiatry (2010) 0.93
Comparison of healthcare utilization among patients treated with alcoholism medications. Am J Manag Care (2010) 0.93
Extended-release naltrexone for alcohol dependence: persistence and healthcare costs and utilization. Am J Manag Care (2011) 0.93
Extended-release naltrexone for alcohol and opioid dependence: a meta-analysis of healthcare utilization studies. J Subst Abuse Treat (2014) 0.93
Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients. Alcohol Clin Exp Res (2008) 0.90
Adoption of injectable naltrexone in U.S. substance use disorder treatment programs. J Stud Alcohol Drugs (2015) 0.85
Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community. Contemp Clin Trials (2013) 0.85
A randomized trial evaluating an mHealth system to monitor and enhance adherence to pharmacotherapy for alcohol use disorders. Addict Sci Clin Pract (2012) 0.83
Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system. Drug Alcohol Depend (2015) 0.82
Effects of naltrexone treatment for alcohol-related disorders on healthcare costs in an insured population. Alcohol Clin Exp Res (2010) 0.79
A pharmaceutical industry perspective on the economics of treatments for alcohol and opioid use disorders. Ann N Y Acad Sci (2014) 0.78
Improving clinical outcomes for naltrexone as a management of problem alcohol use. Br J Clin Pharmacol (2013) 0.78
Drug therapy for alcohol dependence in primary care in the UK: A Clinical Practice Research Datalink study. PLoS One (2017) 0.75
Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community. Drug Alcohol Depend (2017) 0.75
Disparities in Pharmacotherapy for Alcohol Use Disorder in the Context of Universal Healthcare: A Swedish Register Study. Addiction (2017) 0.75
The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991-1992 and 2001-2002. Drug Alcohol Depend (2004) 13.53
The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry (1993) 9.09
Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc (2006) 5.32
Perceived need and help-seeking in adults with mood, anxiety, or substance use disorders. Arch Gen Psychiatry (2002) 3.71
Alcohol treatment utilization: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug Alcohol Depend (2006) 3.40
Problem drinking and medication adherence among persons with HIV infection. J Gen Intern Med (2001) 2.81
Understanding US addiction physicians' low rate of naltrexone prescription. Drug Alcohol Depend (2003) 1.86
Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value Health (2003) 1.68
Assessment of medication compliance in alcoholics through UV light detection of a riboflavin tracer. Alcohol Clin Exp Res (1996) 1.67
Treatment adherence with antipsychotic medications in bipolar disorder. Bipolar Disord (2006) 1.66
Improving naltrexone response: an intervention for medical practitioners to enhance medication compliance in alcohol dependent patients. J Addict Dis (2000) 1.62
Use of substance abuse treatment services by persons with mental health and substance use problems. Psychiatr Serv (2003) 1.61
A structured approach to medical management: a psychosocial intervention to support pharmacotherapy in the treatment of alcohol dependence. J Stud Alcohol Suppl (2005) 1.47
Adherence to pharmacotherapy in patients with alcohol and opioid dependence. Addiction (2004) 1.43
Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment. J Clin Psychopharmacol (2007) 1.42
Alcohol dependence: a public health perspective. Addiction (2002) 1.30
What role does measuring medication compliance play in evaluating the efficacy of naltrexone? Alcohol Clin Exp Res (2007) 1.26
The BRENDA model: integrating psychosocial treatment and pharmacotherapy for the treatment of alcohol use disorders. J Psychiatr Pract (2006) 1.19
Pharmacotherapy of alcoholism: gaps in knowledge and opportunities for research. Alcohol Alcohol (2001) 1.18
Correlates of a perceived need for mental health assistance and differences between those who do and do not seek help. Soc Psychiatry Psychiatr Epidemiol (1999) 1.16
Datapoints: Trends in naltrexone use among members of a large private health plan. Psychiatr Serv (2004) 1.04
Measurement and prediction of medication compliance in problem drinkers. Alcohol Clin Exp Res (2003) 1.02
Patterns of dispensed disulfiram and naltrexone for alcoholism treatment in a veteran patient population. Alcohol Clin Exp Res (2004) 0.96
Alcohol consumption and compliance among inner-city minority patients with type 2 diabetes mellitus. Arch Fam Med (2001) 0.95
Diabetic patients' alcohol use and quality of life: relationships with prescribed treatment compliance among older males. Alcohol Clin Exp Res (1996) 0.92
Adherence and persistence with single-dosage form extended-release niacin/lovastatin compared with statins alone or in combination with extended-release niacin. Ann Pharmacother (2006) 0.89
Alcohol use and adherence to prescribed therapy among under-served Latino and African-American patients using emergency department services. Ethn Dis (2005) 0.87
Disulfiram (antabuse) contracts in treatment of alcoholism. NIDA Res Monogr (1995) 0.84
Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA (2006) 13.15
Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet (2011) 6.35
Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA (2005) 4.64
Health, absence, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting U.S. employers. J Occup Environ Med (2004) 3.43
The health and productivity cost burden of the "top 10" physical and mental health conditions affecting six large U.S. employers in 1999. J Occup Environ Med (2003) 3.09
The direct and indirect costs of untreated insomnia in adults in the United States. Sleep (2007) 2.58
Insomnia and the performance of US workers: results from the America insomnia survey. Sleep (2011) 1.77
Addiction denial and cognitive dysfunction: a preliminary investigation. J Neuropsychiatry Clin Neurosci (2002) 1.76
The effects of prescription drug copayments on statin adherence. Am J Manag Care (2006) 1.65
Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther (2010) 1.64
The relationship between cocaine craving, psychosocial treatment, and subsequent cocaine use. Am J Psychiatry (2003) 1.63
Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. Addiction (2013) 1.63
The effect of 12-step self-help group attendance and participation on drug use outcomes among cocaine-dependent patients. Drug Alcohol Depend (2005) 1.55
Physician substance abuse and recovery: what does it mean for physicians--and everyone else? JAMA (2005) 1.53
Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment. J Clin Psychopharmacol (2007) 1.42
Decreased absolute amygdala volume in cocaine addicts. Neuron (2004) 1.41
The direct and indirect cost burden of clinically significant and symptomatic uterine fibroids. J Occup Environ Med (2007) 1.19
Nighttime insomnia symptoms and perceived health in the America Insomnia Survey (AIS). Sleep (2011) 1.19
Retention in psychosocial treatment of cocaine dependence: predictors and impact on outcome. Am J Addict (2002) 1.12
Sertraline treatment of co-occurring alcohol dependence and major depression. J Clin Psychopharmacol (2006) 1.12
Health care utilization and expenditures in the United States: a study of osteoporosis-related fractures. Osteoporos Int (2004) 1.12
Acamprosate efficacy in alcohol-dependent patients: summary of results from three pivotal trials. Am J Addict (2008) 1.11
The direct and indirect cost burden of Crohn's disease and ulcerative colitis. J Occup Environ Med (2008) 1.10
Concern The cost burden of oral, oral pharyngeal, and salivary gland cancers in three groups: commercial insurance, Medicare, and Medicaid. Head Neck Oncol (2012) 1.09
Reliability and validity of the brief insomnia questionnaire in the America insomnia survey. Sleep (2010) 1.08
Development of the Environmental Assessment Tool (EAT) to measure organizational physical and social support for worksite obesity prevention programs. J Occup Environ Med (2008) 1.08
The associations of insomnia with costly workplace accidents and errors: results from the America Insomnia Survey. Arch Gen Psychiatry (2012) 1.07
Prevalence of physical and sexual abuse among substance abuse patients and impact on treatment outcomes. Drug Alcohol Depend (2004) 1.07
Advancing performance measures for use of medications in substance abuse treatment. J Subst Abuse Treat (2010) 1.03
Cost and utilization outcomes of opioid-dependence treatments. Am J Manag Care (2011) 1.03
Uterine fibroid treatment patterns in a population of insured women. Fertil Steril (2008) 1.02
What are the total costs of surgical treatment for uterine fibroids? J Womens Health (Larchmt) (2008) 1.01
Medication-assisted treatment with buprenorphine: assessing the evidence. Psychiatr Serv (2014) 1.01
Alcohol dependence treatments: comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence. Am J Manag Care (2011) 0.99
The relationship between modifiable health risk factors and medical expenditures, absenteeism, short-term disability, and presenteeism among employees at novartis. J Occup Environ Med (2009) 0.98
Direct and indirect costs to employers of patients with systemic lupus erythematosus with and without nephritis. J Occup Environ Med (2009) 0.97
The long-term impact of Johnson & Johnson's Health & Wellness Program on employee health risks. J Occup Environ Med (2002) 0.97
Factorial designs in clinical trials: options for combination treatment studies. J Stud Alcohol Suppl (2005) 0.97
Insomnia, comorbidity, and risk of injury among insured Americans: results from the America Insomnia Survey. Sleep (2012) 0.95
Economic burden of osteoporosis-related fractures in Medicaid. Value Health (2007) 0.95
The impact of rheumatoid arthritis on medical expenditures, absenteeism, and short-term disability benefits. J Occup Environ Med (2006) 0.95
Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-abusing adults: dose-effects and time-course. Drug Alcohol Depend (2011) 0.95
Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population. J Manag Care Spec Pharm (2014) 0.94
Dose trends for second-generation antipsychotic treatment of schizophrenia and bipolar disorder. Schizophr Res (2008) 0.93
Cost effectiveness of long-term treatment with eszopiclone for primary insomnia in adults: a decision analytical model. CNS Drugs (2007) 0.93
Comparison of healthcare utilization among patients treated with alcoholism medications. Am J Manag Care (2010) 0.93
The economic value of specialized lower-extremity medical care by podiatric physicians in the treatment of diabetic foot ulcers. J Am Podiatr Med Assoc (2011) 0.91
First-year results of an obesity prevention program at The Dow Chemical Company. J Occup Environ Med (2009) 0.90
Cocaine-primed craving and its relationship to depressive symptomatology in individuals with cocaine dependence. J Psychopharmacol (2002) 0.90
Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients. Alcohol Clin Exp Res (2008) 0.90
Design and analysis of trials of combination therapies. J Stud Alcohol Suppl (2005) 0.90
Impact of asthma controller medications on medical and economic resource utilization in adult asthma patients. Curr Med Res Opin (2010) 0.88
Long-term opioid blockade and hedonic response: preliminary data from two open-label extension studies with extended-release naltrexone. Am J Addict (2010) 0.88
Characteristics affecting oral anticoagulant therapy choice among patients with non-valvular atrial fibrillation: a retrospective claims analysis. BMC Health Serv Res (2014) 0.87
The relationship between health risks and health and productivity costs among employees at Pepsi Bottling Group. J Occup Environ Med (2010) 0.87
The use of disease-modifying new drugs for multiple sclerosis treatment in private-sector health plans. Clin Ther (2004) 0.86
No-Show for Treatment in Substance Abuse Patients with Comorbid Symptomatology: Validity Results from a Controlled Trial of the ASAM Patient Placement Criteria. J Addict Med (2007) 0.86
Validation of the Addiction Severity Index (ASI) for internet and automated telephone self-report administration. J Subst Abuse Treat (2004) 0.86
Healthcare costs among patients with chronic constipation: a retrospective claims analysis in a commercially insured population. J Med Econ (2013) 0.86
Cost of illness and comorbidities in adults diagnosed with attention-deficit/hyperactivity disorder: a retrospective analysis. Prim Care Companion CNS Disord (2011) 0.84
Healthcare utilization and costs of patients with rosacea in an insured population. J Drugs Dermatol (2008) 0.83
Risk of injury associated with attention-deficit/hyperactivity disorder in adults enrolled in employer-sponsored health plans: a retrospective analysis. Prim Care Companion CNS Disord (2011) 0.83
Injectable extended-release naltrexone for opioid dependence. Lancet (2011) 0.83
Middle-of-the-night hypnotic use in a large national health plan. J Clin Sleep Med (2013) 0.82
Effects of injectable extended-release naltrexone (XR-NTX) for opioid dependence on residential rehabilitation outcomes and early follow-up. Am J Addict (2015) 0.82
Impact of natalizumab on patient-reported outcomes in a clinical practice setting: a cross-sectional survey. Patient (2009) 0.82
Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX): Who Will Respond? J Addict Med (2015) 0.81
Economic impact of tobramycin in patients with cystic fibrosis in a managed care population. J Med Econ (2011) 0.81
Treatment pattern changes in high-risk patients newly initiated on statin monotherapy in a managed care setting. J Clin Lipidol (2013) 0.81
Days-out-of-role associated with insomnia and comorbid conditions in the America Insomnia Survey. Biol Psychiatry (2011) 0.80
Propensity score matched assessment of treatment patterns and cost of erythropoiesis stimulating agent treatment in patients with cancer receiving myelosuppressive chemotherapy. J Oncol Pharm Pract (2012) 0.79
Early treatment response in alcohol dependence with extended-release naltrexone. J Clin Psychiatry (2008) 0.79
National Breakthrough Pain Study: prevalence, characteristics, and associations with health outcomes. Pain (2015) 0.79
Effects of naltrexone treatment for alcohol-related disorders on healthcare costs in an insured population. Alcohol Clin Exp Res (2010) 0.79
Determining service variations between and within ASAM levels of care. J Addict Dis (2003) 0.79
Impact of non-remission of depression on costs and resource utilization: from the COmorbidities and symptoms of DEpression (CODE) study. Curr Med Res Opin (2015) 0.79
Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence. Alcohol Clin Exp Res (2011) 0.79
Absenteeism among employees with irritable bowel syndrome. Manag Care Interface (2004) 0.78
Predictive validity of the ASAM Patient Placement Criteria for hospital utilization. J Addict Dis (2003) 0.78
Patient characteristics and prescription fill patterns for allergic rhinitis medications, with a focus on montelukast, in a commercially insured population. Clin Ther (2010) 0.77
Reliability of multidimensional substance abuse treatment matching: implementing the ASAM Patient Placement Criteria. J Addict Dis (2003) 0.77
Impact of treatment with intramuscular, injectable, extended-release naltrexone on counseling and support group participation in patients with alcohol dependence. J Addict Med (2010) 0.77
Overriding the blockade of antinociceptive actions of opioids in rats treated with extended-release naltrexone. Pharmacol Biochem Behav (2008) 0.77
Antithrombotic medication use and bleeding risk in medically ill patients after hospitalization. Clin Appl Thromb Hemost (2013) 0.76
Thromboprophylaxis patterns, risk factors, and outcomes of care in the medically ill patient population. Thromb Res (2013) 0.76
The ASAM patient placement criteria: context, concepts and continuing development. J Addict Dis (2003) 0.76
Olanzapine-induced hyperventilation: case report. J Psychiatry Neurosci (2002) 0.75
Impact of access restrictions on varenicline utilization. Expert Rev Pharmacoecon Outcomes Res (2013) 0.75
Advances in the pharmacotherapy of alcoholism: challenging misconceptions. Alcohol Clin Exp Res (2006) 0.75
All-cause mortality and use of antithrombotics within 90 days of discharge in acutely ill medical patients. Thromb Haemost (2015) 0.75
Visual inspection of medications in preventing unexplained relapses. Ann Pharmacother (2002) 0.75
Open-label Study of Injectable Extended-release Naltrexone (XR-NTX) in Healthcare Professionals With Opioid Dependence. J Addict Med (2017) 0.75